NDA 021411 · Lilly
Strattera
Atomoxetine Hydrochloride · Oral
NovelDiscontinuedLast checked: Nov 20, 2026Latest source record: Jun 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Nov 26, 2002
Approved uses
5
Original approval plus efficacy supplements
Registered trials
195
41 Phase 3, 13 recruiting
FAERS reports
23,874
9,462 serious, 1,574 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER All STRATTERA-treated pediatric patients 6 years of age or older should be monitored and observed closely for suicidal thoughts and behavior, clinical worsening, or unusual changes in behavior, especially during the initial months of therapy or at times of dosage changes. Families and caregivers should be advised of the need for close observation and communication with the health care provider. Consider stopping STRATTERA in patients who experience emergent suicidal thoughts and behavior [see Warnings and Precautions ( 5.1 )]. STRATTERA increased the risk of suicidal ideation in pediatric patients aged 6 years of age and older with attention-deficit/hyperactivity disorder (ADHD) in short-term studies. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER See full...
What it is approved for
From the label in effect Jun 30, 2026.
STRATTERA is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients 6 years of age and older. STRATTERA is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with ADHD. STRATTERA ® is a selective norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of ADHD in adults and pediatric patients 6 years of age and older. ( 1 )
Mechanism: The precise mechanism by which STRATTERA produces its therapeutic effects in ADHD is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined in ex vivo uptake and neurotransmitter depletion studies.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 23, 2008 Supplement 24 · Efficacy LetterLabel
- May 7, 2008 Supplement 5 · Efficacy Summary ReviewLetter
- Sep 28, 2007 Supplement 19 · Efficacy LabelLetter
- May 26, 2005 Supplement 8 · Efficacy Letter
- Nov 26, 2002 Original approval · Type 1 - New Molecular Entity NovelReviewLetterLabel
8 products under this application
- STRATTERA · ATOMOXETINE HYDROCHLORIDE EQ 80MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued · TE AB
- STRATTERA · ATOMOXETINE HYDROCHLORIDE EQ 40MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued · TE AB
- STRATTERA · ATOMOXETINE HYDROCHLORIDE EQ 18MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued · TE AB
- STRATTERA · ATOMOXETINE HYDROCHLORIDE EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
- STRATTERA · ATOMOXETINE HYDROCHLORIDE EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued · TE AB
- STRATTERA · ATOMOXETINE HYDROCHLORIDE EQ 60MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued · TE AB
- STRATTERA · ATOMOXETINE HYDROCHLORIDE EQ 25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued · TE AB
- STRATTERA · ATOMOXETINE HYDROCHLORIDE EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Atomoxetine" as an intervention, any sponsor and status, largest first.
- A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in AdultsPivotal-lookingRecruiting
Sairam ParthasarathyAcademic, hospital or other
NCT07679282 · 2,400 participants (planned) · Start Sep 4, 2026 · Primary completion Mar 1, 2030
Drug: Atomoxetine-oxybutynin · For: Obstructive Sleep Apnea (OSA)
Sites: Tucson, Arizona; Redwood City, California; Miami, Florida · 4 sites in all
- A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00700427 · 2,017 participants · Start Jun 2008 · Primary completion Aug 2011
Drug: atomoxetine hydrochloride; Placebo · For: Attention Deficit Hyperactivity Disorder
Sites: Vienna, Austria; Bruges, Belgium; Kortenberg, Belgium · 56 sites in all
- Long-Term, Open Label Atomoxetine StudyPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00190684 · 1,553 participants · Start Aug 2000 · Primary completion Oct 2009
Drug: atomoxetine · For: Attention Deficit Hyperactivity Disorder
Sites: Birmingham, Alabama; Phoenix, Arizona; El Centro, California · 100 sites in all
- Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity DisorderPivotal-lookingCompleted
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Industry
NCT00866996 · 1,323 participants
Drug: Methylphenidate extended-release; Atomoxetine · For: Attention Deficit Hyperactivity Disorder
- Continuation Protocol for Obstructive Sleep Apnea (OSA)Pivotal-lookingEnrolling by invitation
ApnimedIndustry
NCT06566820 · 1,280 participants (planned) · Start Jul 3, 2024 · Primary completion Jun 30, 2026
Drug: Aroxybutynin and Atomoxetine · For: OSA
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Chandler, Arizona · 99 sites in all
- An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's DiseasePivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT07724132 · 1,200 participants (planned) · Start Jul 24, 2026 · Primary completion Mar 2031
Drug: Placebo; Atomoxetine and 1 more · For: Alzheimer's Disease (AD); Mild Cognitive Impairment Due to Alzheimer's Disease; Alzheimer Disease Dementia
Sites: Cambridge, United Kingdom; Chertsey, United Kingdom
- Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)Pivotal-lookingCompleted
ApnimedIndustry
NCT05811247 · 660 participants · Start Aug 28, 2023 · Primary completion May 7, 2025
Drug: AD109; Placebo · For: OSA
Sites: Birmingham, Alabama; Chandler, Arizona; Little Rock, Arkansas · 64 sites in all
- Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)Pivotal-lookingCompleted
ApnimedIndustry
NCT05813275 · 646 participants · Start Sep 16, 2023 · Primary completion Mar 10, 2025
Drug: AD109; Placebo · For: OSA
Sites: Tuscaloosa, Alabama; Mesa, Arizona; Phoenix, Arizona · 73 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective2,439
- fatigue1,931
- nausea1,898
- vomiting1,522
- headache1,510
- dizziness1,430
- somnolence1,361
- off label use1,304
- insomnia1,281
- depression1,198
- feeling abnormal1,186
- abdominal pain upper1,181
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 5,235 |
| 2005 | 3,700 |
| 2006 | 579 |
| 2007 | 510 |
| 2008 | 415 |
| 2009 | 557 |
| 2010 | 398 |
| 2011 | 414 |
| 2012 | 474 |
| 2013 | 409 |
| 2014 | 534 |
| 2015 | 4,499 |
| 2016 | 808 |
| 2017 | 508 |
| 2018 | 416 |
| 2019 | 441 |
| 2020 | 355 |
| 2021 | 296 |
| 2022 | 366 |
| 2023 | 441 |
| 2024 | 722 |
| 2025 | 1,215 |
| 2026 | 582 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Strattera (Atomoxetine HCl)
2024 spending
$1.4M
Beneficiaries
310
1,738 claims
Per beneficiary
$4,392
$14.14 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,906,903 |
| 2021 | $1,599,259 |
| 2022 | $1,585,726 |
| 2023 | $1,546,386 |
| 2024 | $1,361,505 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
Cortese S, Adamo N, Del Giovane C, et al. · Lancet Psychiatry 2018 · Comparative Study, Research Support, Non-U.S. Gov't
- Systematic Review and Meta-Analysis: Effects of Pharmacological Treatment for Attention-Deficit/Hyperactivity Disorder on Quality of Life.
Bellato A, Perrott NJ, Marzulli L, et al. · J Am Acad Child Adolesc Psychiatry 2025 · Systematic Review, Network Meta-Analysis
- Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis.
Ostinelli EG, Schulze M, Zangani C, et al. · Lancet Psychiatry 2025 · Comparative Study, Network Meta-Analysis
- Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.
Siafis S, Çray O, Wu H, et al. · Mol Autism 2022 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Cardiovascular Effects of ADHD Therapies: JACC Review Topic of the Week.
Torres-Acosta N, O'Keefe JH, O'Keefe CL, et al. · J Am Coll Cardiol 2020 · Systematic Review
- Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Elliott J, Johnston A, Husereau D, et al. · PLoS One 2020 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.